Kyungdong Pharmaceutical's Combination Drug for Benign Prostatic Hyperplasia Succeeds in Phase 3 Clinical Trial: "Improvement Confirmed"

Kyungdong Pharmaceutical announced on the 12th that it has successfully completed the domestic Phase 3 clinical trial of KDF1905-2BO, an improved new drug combination for benign prostatic hyperplasia (BPH).

KDF1905-2BO is a combination drug that merges tamsulosin (KDF1905-R1), a representative alpha-blocker for BPH, with mirabegron (KDF1905-R2), an ingredient for treating overactive bladder. Tamsulosin and mirabegron are widely prescribed drugs in the urological field.

The Phase 3 clinical trial was conducted to demonstrate the efficacy and safety of KDF1905-2BO in patients with BPH. The trial was carried out at 25 institutions in Korea, including Dong-A University Hospital, involving 795 patients. It was designed as a randomized, double-blind, parallel, placebo-controlled, therapeutic confirmation study.

Through the clinical trial, the company demonstrated the improvement of lower urinary tract symptoms in the group receiving combined administration of KDF1905-R1 and KDF1905-R2. The combination group showed superior effects compared to the KDF1905-R1 monotherapy group in the primary efficacy endpoint, the change in urgency and frequency scores (TUFS) at 12 weeks after administration. Additionally, the combination group confirmed non-inferiority in the change of the total International Prostate Symptom Score (IPSS) at 12 weeks after administration.

A company representative stated, "Due to population aging and changes in dietary habits, the number of patients with BPH, a representative urological disease, is on the rise. With the success of the Phase 3 clinical trial, we will expedite the approval of the improved new combination drug for BPH with enhanced therapeutic effects and actively pursue market entry.”

This content was produced with the assistance of AI translation services.